155 related articles for article (PubMed ID: 28087047)
1. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
2. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
3. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Mazor R; Eberle JA; Hu X; Vassall AN; Onda M; Beers R; Lee EC; Kreitman RJ; Lee B; Baker D; King C; Hassan R; Benhar I; Pastan I
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8571-6. PubMed ID: 24799704
[TBL] [Abstract][Full Text] [Related]
4. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of therapeutic recombinant immunotoxins.
Mazor R; Onda M; Pastan I
Immunol Rev; 2016 Mar; 270(1):152-64. PubMed ID: 26864110
[TBL] [Abstract][Full Text] [Related]
6. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins.
Roscoe DM; Pai LH; Pastan I
Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
8. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
9. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
11. Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.
Hu X; Zhang M; Zhang C; Long S; Wang W; Yin W; Cao Z
J BUON; 2016; 21(6):1374-1378. PubMed ID: 28039694
[TBL] [Abstract][Full Text] [Related]
12. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
13. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
Onda M; Willingham M; Wang QC; Kreitman RJ; Tsutsumi Y; Nagata S; Pastan I
J Immunol; 2000 Dec; 165(12):7150-6. PubMed ID: 11120846
[TBL] [Abstract][Full Text] [Related]
16. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
Singh R; Zhang Y; Pastan I; Kreitman RJ
Clin Cancer Res; 2012 Jan; 18(1):152-60. PubMed ID: 22068660
[TBL] [Abstract][Full Text] [Related]
18. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Powell DJ; Felipe-Silva A; Merino MJ; Ahmadzadeh M; Allen T; Levy C; White DE; Mavroukakis S; Kreitman RJ; Rosenberg SA; Pastan I
J Immunol; 2007 Oct; 179(7):4919-28. PubMed ID: 17878392
[TBL] [Abstract][Full Text] [Related]
19. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I
Leukemia; 1993 Apr; 7(4):553-62. PubMed ID: 8464234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
